An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place. This story matters for Finance & Markets readers tracking expo. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. Expo-News curates and briefs the finance & markets stories that matter. Our editorial policy →